<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROSTIN  VR PEDIATRIC- alprostadil injection, solution </strong><br>Pharmacia and Upjohn Company<br></p></div>
<h1>Prostin VR Pediatric<span class="Sup">®</span><br>alprostadil injection, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">500 micrograms per mL</span></p>
</div>
<div class="Warning">
<a name="Warning_Box"></a><a name="section-2"></a><p></p>
<h1><span class="Emphasis">WARNING</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> is experienced by about 10 to 12% of neonates with congenital heart defects treated with PROSTIN VR PEDIATRIC Sterile Solution. <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> is most often seen in neonates weighing less than 2 kg at birth and usually appears during the first hour of drug infusion. Therefore, respiratory status should be monitored throughout treatment, and PROSTIN VR PEDIATRIC should be used where ventilatory assistance is immediately available.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">PROSTIN VR PEDIATRIC Sterile Solution for intravascular infusion contains 500 micrograms alprostadil, more commonly known as prostaglandin E<span class="Sub">1</span>, in 1.0 mL dehydrated alcohol.</p>
<p>The chemical name for alprostadil is (11α,13E,15S)-11,15 dihydroxy-9-oxo-prost-13-en-1-oic acid, and the molecular weight is 354.49.</p>
<p>Alprostadil is a white to off-white crystalline powder with a melting point between 110° and 116°C. Its solubility at 35°C is 8000 micrograms per 100 mL double distilled water.</p>
<p><span class="Bold">Structural Formula</span></p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dea460fa-d05e-4191-8461-f185a711ad89&amp;name=prostin-vr-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Alprostadil (prostaglandin E<span class="Sub">1</span>) is one of a family of naturally occurring acidic lipids with various pharmacologic effects. Vasodilation, inhibition of platelet aggregation, and stimulation of intestinal and uterine smooth muscle are among the most notable of these effects. Intravenous doses of 1 to 10 micrograms of alprostadil per kilogram of body weight lower the blood pressure in mammals by decreasing peripheral resistance. Reflex increases in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and rate accompany the reduction in blood pressure.</p>
<p>Smooth muscle of the ductus arteriosus is especially sensitive to alprostadil, and strips of lamb ductus markedly relax in the presence of the drug. In addition, administration of alprostadil reopened the closing ductus of new-born rats, rabbits, and lambs. These observations led to the investigation of alprostadil in infants  who had congenital defects which restricted the pulmonary or systemic blood flow and who depended on a <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> for adequate blood oxygenation and lower body perfusion.</p>
<p>In infants with restricted pulmonary blood flow, about 50% responded to alprostadil infusion with at least a 10 torr increase in blood pO<span class="Sub">2</span> (mean increase about 14 torr and mean increase in oxygen saturation about 23%). In general, patients who responded best had low pretreatment blood pO<span class="Sub">2</span> and were 4 days old or less.</p>
<p>In infants with restricted systemic blood flow, alprostadil often increased pH in those having <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, increased systemic blood pressure, and decreased the ratio of pulmonary artery pressure to aortic pressure.</p>
<p>Alprostadil must be infused continuously because it is very rapidly metabolized. As much as 80% of the circulating alprostadil may be metabolized in one pass through the lungs, primarily by β- and ω- oxidation. The metabolites are excreted primarily by the kidney, and excretion is essentially complete within 24 hours after administration. No unchanged alprostadil has been found in the urine, and there is no evidence of tissue retention of alprostadil or its metabolites.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, <span class="product-label-link" type="condition" conceptid="4209011" conceptname="Pulmonic valve stenosis">pulmonary stenosis</span>, tricuspid atresia, <span class="product-label-link" type="condition" conceptid="320835" conceptname="Tetralogy of Fallot">tetralogy of Fallot</span>, interruption of the aortic arch, <span class="product-label-link" type="condition" conceptid="321119" conceptname="Coarctation of aorta">coarctation of the aorta</span>, or transposition  of the great vessels with or without other defects.</p>
<p>In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO<span class="Sub">2</span> values; that is, patients with low pO<span class="Sub">2</span> values respond best, and patients with pO<span class="Sub">2</span> values of 40 torr or more usually have little response.</p>
<p>PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">See <a href="#Warning_Box">WARNING</a> box.</p>
<p><span class="Bold">NOTE:</span> PROSTIN VR PEDIATRIC Sterile Solution must be diluted before it is administered. See <a href="#Dilution_Instr">dilution instructions in DOSAGE AND ADMINISTRATION</a> section.</p>
<p>The administration of PROSTIN VR PEDIATRIC to neonates may result in <span class="product-label-link" type="condition" conceptid="198191" conceptname="Acquired hypertrophic pyloric stenosis">gastric outlet obstruction</span> secondary to antral <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>. This effect appears to be related to duration of therapy and cumulative dose of the drug. Neonates receiving PROSTIN VR PEDIATRIC at recommended doses for more than 120 hours should be closely monitored for evidence of antral <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and <span class="product-label-link" type="condition" conceptid="198191" conceptname="Acquired hypertrophic pyloric stenosis">gastric outlet obstruction</span>.</p>
<p>PROSTIN VR PEDIATRIC should be infused for the shortest time and at the lowest dose that will produce the desired effects. The risks of long-term infusion of PROSTIN VR PEDIATRIC should be weighed against the possible benefits that critically ill infants may derive from its administration.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General Precautions</h2>
<p class="First">Cortical proliferation of the long bones, first observed in dogs, has also been observed in infants during long-term infusions of alprostadil. The cortical proliferation in infants regressed after withdrawal of the drug.</p>
<p>In infants treated with PROSTIN VR PEDIATRIC at the usual doses for 10 hours to 12 days and who died of causes unrelated to ductus structural <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, tissue sections of the ductus and pulmonary arteries have shown intimal <span class="product-label-link" type="condition" conceptid="443419" conceptname="Laceration - injury">lacerations</span>, a decrease in medial muscularity and disruption of the medial and internal elastic lamina. Localized and aneurysmal dilatations and vessel wall <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> also were seen compared to a series of pathological specimens from infants not treated with PROSTIN VR PEDIATRIC. The incidence of such structural alterations has not been defined.</p>
<p>Because alprostadil inhibits platelet aggregation, use PROSTIN VR PEDIATRIC cautiously in neonates with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies.</p>
<p>PROSTIN VR PEDIATRIC should not be used in neonates with <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> syndrome. A differential diagnosis should be made between <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> syndrome (<span class="product-label-link" type="condition" conceptid="258866" conceptname="Respiratory distress syndrome in the newborn">hyaline membrane disease</span>) and cyanotic heart disease (restricted pulmonary blood flow). If full diagnostic facilities are not immediately available, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> (pO<span class="Sub">2</span> less than 40 torr) and restricted pulmonary blood flow apparent on an X-ray are appropriate indicators of congenital heart defects.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<h3>Necessary Monitoring</h3>
<p class="First">In all neonates, arterial pressure should be monitored intermittently by umbilical artery catheter, auscultation, or with a Doppler transducer. <span class="Italics">Should arterial pressure <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> significantly, decrease the rate of infusion immediately.</span></p>
<p>In infants with restricted pulmonary blood flow, measure efficacy of PROSTIN VR PEDIATRIC by monitoring improvement in blood oxygenation. In infants with restricted systemic blood flow, measure efficacy by monitoring improvement of systemic blood pressure and blood pH.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">No drug interactions have been reported between PROSTIN VR PEDIATRIC and the therapy standard in neonates with restricted pulmonary or systemic blood flow. Standard therapy includes antibiotics, such as penicillin and gentamicin; vasopressors, such as dopamine and isoproterenol; cardiac glycosides; and diuretics, such as furosemide.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<p class="First">Long-term carcinogenicity studies and fertility studies have not been done. The Ames and Alkaline Elution assays reveal no potential for mutagenesis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> has been reported in about 12% of the neonates treated.</span> (See <a href="#Warning_Box">WARNING</a> box.) Other common adverse reactions reported have been <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> in about 14% of the patients treated and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in about 4%. The following reactions have been reported in less than 1% of the patients: cerebral <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, hyperextension of the neck, hyperirritability, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, and <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Cardiovascular System</h2>
<p class="First">The most common adverse reactions reported have been <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> in about 10% of patients (more common after intraarterial dosing), <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> in about 7%, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in about 4%, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> in about 3%, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> in about 1%, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> in about 1%. The following reactions have been reported in less than 1% of the patients: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4146766" conceptname="Hyperemia">hyperemia</span>, second degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, spasm of the right ventricle infundibulum, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Respiratory System</h2>
<p class="First">The following reactions have been reported in less than 1% of the patients: <span class="product-label-link" type="condition" conceptid="4314808" conceptname="Slow respiration">bradypnea</span>, bronchial <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, and <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2>Gastrointestinal System</h2>
<p class="First">See <a href="#Warnings">WARNINGS</a></p>
<p>The most common adverse reaction reported has been <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in about 2% of the patients. The following reactions have been reported in less than 1% of the patients: gastric <span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">regurgitation</span>, and <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2>Hematologic System</h2>
<p class="First">The most common hematologic event reported has been <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span> in about 1% of the patients. The following events have been reported in less than 1% of the patients: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>Excretory System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> have been reported in less than 1% of the patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7"></a><p></p>
<h2>Skeletal System</h2>
<p class="First">Cortical proliferation of the long bones has been reported. See <a href="#Precautions">PRECAUTIONS</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.8"></a><p></p>
<h2>Miscellaneous</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span> has been reported in about 2% of the patients. <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">Peritonitis</span> has been reported in less than 1% of the patients. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> has been reported in about 1%, and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> have been reported in less than 1% of the patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> may be signs of drug overdosage. If <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> occurs, discontinue the infusion, and provide appropriate medical treatment. Caution should be used in restarting the infusion. If <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, reduce the infusion rate until these symptoms subside. <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span> is usually a result of incorrect intraarterial catheter placement, and the catheter should be repositioned.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Dosage_And_Administration"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The preferred route of administration for PROSTIN VR PEDIATRIC Sterile Solution is continuous intravenous infusion into a large vein. Alternatively, PROSTIN VR PEDIATRIC may be administered through an umbilical artery catheter placed at the ductal opening. Increases in blood pO<span class="Sub">2</span> (torr) have been the same in neonates who received the drug by either route of administration.</p>
<p>Begin infusion with 0.05 to 0.1 micrograms alprostadil per kilogram of body weight per minute. A starting dose of 0.1 micrograms per kilogram of body weight per minute is the recommended starting dose based on clinical studies; however, adequate clinical response has been reported using a starting dose of 0.05 micrograms per kilogram of body weight per minute. After a therapeutic response is achieved (increased pO<span class="Sub">2</span> in infants with restricted pulmonary blood flow or increased systemic blood pressure and blood pH in infants with restricted systemic blood flow), reduce the infusion rate to provide the lowest possible dosage that maintains the response. This may be accomplished by reducing the dosage from 0.1 to 0.05 to 0.025 to 0.01 micrograms per kilogram of body weight per minute. If response to 0.05 micrograms per kilogram of body weight per minute is inadequate, dosage can be increased up to 0.4 micrograms per kilogram of body weight per minute although, in general, higher infusion rates do not produce greater effects.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Dilution_Instr"></a><a name="section-10.1"></a><p></p>
<h2>Dilution Instructions</h2>
<p class="First">To prepare infusion solutions, dilute 1 mL of PROSTIN VR PEDIATRIC Sterile Solution with Sodium Chloride Injection USP or Dextrose Injection USP. Undiluted PROSTIN VR PEDIATRIC Sterile Solution may interact with the plastic sidewalls of volumetric infusion chambers causing a change in the appearance of the chamber and creating a hazy solution. Should this occur, the solution and the volumetric infusion chamber should be replaced.</p>
<p>When using a volumetric infusion chamber, the appropriate amount of intravenous infusion solution should be added to the chamber first. The undiluted PROSTIN VR PEDIATRIC Sterile Solution should then be added to the intravenous infusion solution, avoiding direct contact of the undiluted solution with the walls of the volumetric infusion chamber.</p>
<p>Dilute to volumes appropriate for the pump delivery system available. Prepare fresh infusion solutions every 24 hours. <span class="Italics">Discard any solution more than 24 hours old.</span></p>
<table width="90%">
<caption><span>Sample Dilutions and Infusion Rates to Provide a Dosage of 0.1 Micrograms per Kilogram of Body Weight per Minute</span></caption>
<col align="center" valign="middle" width="33%">
<col align="center" valign="middle" width="34%">
<col align="center" valign="middle" width="33%">
<thead><tr class="First Last">
<th align="center">Add 1 ampoule (500 micrograms) alprostadil to:</th>
<th align="center">Approximate Concentration of resulting solution (micrograms/mL)</th>
<th align="center">Infusion rate (mL/min per kg of body weight)</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">Example: To provide 0.1 micrograms/kilogram of body weight per minute to an infant weighing 2.8 kilograms using a solution of 1 ampoule PROSTIN VR PEDIATRIC in 100 mL of saline or dextrose: INFUSION RATE = 0.02 mL/min per kg × 2.8 kg = 0.056 mL/min or 3.36 mL/hr.</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td align="center">250 mL</td>
<td align="center">2</td>
<td align="center">0.05</td>
</tr>
<tr class="Botrule">
<td align="center">100 mL</td>
<td align="center">5</td>
<td align="center">0.02</td>
</tr>
<tr class="Botrule">
<td align="center">50 mL</td>
<td align="center">10</td>
<td align="center">0.01</td>
</tr>
<tr class="Last">
<td align="center">25 mL</td>
<td align="center">20</td>
<td align="center">0.005</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PROSTIN VR PEDIATRIC Sterile Solution is available in a package of 5 ×1 mL ampoules (NDC 0009-3169-06). Each mL contains 500 micrograms alprostadil in dehydrated alcohol.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First">Store PROSTIN VR PEDIATRIC Sterile Solution in a refrigerator at 2° to 8°C (36° to 46°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dea460fa-d05e-4191-8461-f185a711ad89&amp;name=prostin-vr-02.jpg"></p>
<p>LAB-0013-4.0<br>April 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1 mL Ampoule Label</h1>
<p class="First"><span class="Bold">1 mL</span><br> NDC 0009-3169-01</p>
<p><span class="Bold">Prostin VR Pediatric</span><span class="Sup">®</span><br> alprostadil injection, USP</p>
<p><span class="Bold">500 mcg*</span></p>
<p><span class="Bold">FOR INTRAVASCULAR USE ONLY<br> Refrigerate at 2° to 8°C (36° to 46°F).</span></p>
<p><span class="Bold">DOSAGE AND USE:</span><br> See accompanying prescribing<br> information. <span class="Bold">Dilute before using.</span><br> *Each mL contains: 500 micrograms<br> alprostadil in dehydrated alcohol.</p>
<p>Distributed by Pharmacia &amp; Upjohn Co<br> Division of Pfizer Inc, NY, NY 10017</p>
<p>PAA042607<br><span class="Bold">Rx only</span></p>
<p><span class="Bold">LOT</span></p>
<p><span class="Bold">EXP</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1 mL Ampoule Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dea460fa-d05e-4191-8461-f185a711ad89&amp;name=prostin-vr-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5—1 mL Ampoule Package</h1>
<p class="First">NDC 0009-3169-06<br>Contains 5 of NDC 0009-3169-01</p>
<p><span class="Bold">5—1 mL Ampoules</span></p>
<p><span class="Bold">Prostin VR<br> Pediatric</span><span class="Sup">®</span><br>alprostadil injection, USP</p>
<p><span class="Bold">500 mcg*</span></p>
<p><span class="Bold">FOR INTRAVASCULAR USE ONLY</span></p>
<p><span class="Bold Italics">Pfizer Injectables</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5—1 mL Ampoule Package" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dea460fa-d05e-4191-8461-f185a711ad89&amp;name=prostin-vr-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROSTIN  		
					VR PEDIATRIC</strong><br><span class="contentTableReg">alprostadil injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0009-3169</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAVASCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALPROSTADIL</strong> (ALPROSTADIL) </td>
<td class="formItem">ALPROSTADIL</td>
<td class="formItem">500 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0009-3169-06</td>
<td class="formItem">5  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0009-3169-01</td>
<td class="formItem">1 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018484</td>
<td class="formItem">10/16/1981</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pharmacia and Upjohn Company
							(829076566)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Manufacturing Belgium NV</td>
<td class="formItem"></td>
<td class="formItem">370156507</td>
<td class="formItem">ANALYSIS(0009-3169), MANUFACTURE(0009-3169), PACK(0009-3169)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmacia and Upjohn Company</td>
<td class="formItem"></td>
<td class="formItem">829076566</td>
<td class="formItem">ANALYSIS(0009-3169), API MANUFACTURE(0009-3169), MANUFACTURE(0009-3169), PACK(0009-3169)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d014cf03-a6e6-4f8b-8085-42573a437189</div>
<div>Set id: dea460fa-d05e-4191-8461-f185a711ad89</div>
<div>Version: 7</div>
<div>Effective Time: 20140730</div>
</div>
</div> <div class="DistributorName">Pharmacia and Upjohn Company</div></p>
</body></html>
